We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
 Agilent to Showcases Cancer Research Innovations at AACR 2017
Product News

Agilent to Showcases Cancer Research Innovations at AACR 2017

 Agilent to Showcases Cancer Research Innovations at AACR 2017
Product News

Agilent to Showcases Cancer Research Innovations at AACR 2017


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of " Agilent to Showcases Cancer Research Innovations at AACR 2017"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Agilent Technologies has announced that it will showcase some of its most recent technological advances in the areas of cell analysis and genomics at the AACR Annual Meeting 2017, being held April 1 - 5, 2017 in Washington, D.C. 


Agilent will preview its newest next-generation sequencing (NGS) library prep solution – SureSelectXT HS – providing the first complete target enrichment solution, from quality control to target enrichment to analysis and interpretation, that is optimized for low-input formalin-fixed, paraffin-embedded (FFPE) samples. Additionally, SureSelect XT HS incorporates molecular barcodes, which improves precision and produces higher complexity libraries on a wide range of tissue types.  


“With SureSelectXT HS, researchers will now be able to sequence deeper and achieve greater sensitivity, increasing confidence in their results,” said Rebecca Brandes, global marketing director for Cancer Genetics at Agilent Technologies. “Molecular barcodes increase variant calling accuracy, reduce false positive calls and improve data quality overall.”


Also on show at AACR will be the new Agilent Seahorse XF Glycolytic Rate Assay. This innovative assay is as accurate as a lactate assay, but provides more by reporting real time changes in both central cellular metabolic pathways, enabling the identification of how and when metabolic switches such as the Warburg effect occur. This ability to delineate the different energy pathways used by various tumors will help research scientists develop novel approaches to inhibit cancer cell survival and growth.


“Cancer cells can be dependent on pathways fueled by specific substrates for survival or proliferation, offering an opportunity to identify and confirm metabolic liabilities as therapeutic targets,” said David Ferrick, Ph.D., senior director of the Cell Analysis Division at Agilent Technologies. “The Agilent Seahorse XF assay platform enables the study of metabolic pathways and fuels that cancer cells depend on to generate energy.”  


AACR 2017 will feature seminars and workshops conducted by leading scientists from around the world, including some Agilent customers. Visit Agilent Technologies at booth # 2429 to learn more. 

Advertisement